Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib long-term extension study in APDS/PASLI
NL-OMON54847Phase 2Terminated
- Sponsor
- Pharming Group
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of leniolisib in Activated PI3Kδ syndrome (APDS), sponsored by Pharming Group. Started Dec 2016; status: terminated.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on NL-OMON54847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54847.